Fig. 2.

Comparison of the 95-gene residual risk signature to multi-parametric tests in the validation cohort. a Summary of patients assessed in the validation cohort using the 95-gene residual risk signature and other current multiparametric tests in addition to clinical covariates. Patient samples were ranked according to overall concordance, with all patients called as high-riskor low-risk, across all tests organized at the bottom and top of the heatmap, respectively. Standard clinical covariates such as HER2 status, age, grade, nodal status, stage are included. Molecular subtyping based on the PAM50/Prosigna-like test is also shown. b As performance indicator, area under the receiver operating characteristic (AUC) curves for each multiparametric test is also shown. All patients represented are those who only received endocrine treatment